Dow 
1.48% Nasdaq 1.73%
1.48% Nasdaq 1.73%Nov 27: 3.54 0.10 (2.75%)
0.10 (2.75%) Arena Pharmaceuticals, Inc. (ARNA)
Compare ARNA to:
- Dow Jones (^DJI)
- NASDAQ (^IXIC)
- S&P 500 (^GSPC)
Arena Pharmaceuticals, Inc.
(NasdaqGM: ARNA)After Hours: 3.52 N/A (N/A) 2:13pm ET
| Last Trade: | 3.54 |
|---|---|
| Trade Time: | Nov 27 |
| Change: | 0.10 (2.75%) |
| Prev Close: | 3.64 |
| Open: | 3.53 |
| Bid: | N/A |
| Ask: | 6.50 x 200 |
| 1y Target Est: | 6.46 |
| Day's Range: | 3.50 - 3.64 |
|---|---|
| 52wk Range: | 2.26 - 7.42 |
| Volume: | 719,172 |
| Avg Vol (3m): | 5,356,410 |
| Market Cap: | 328.22M |
| P/E (ttm): | N/A |
| EPS (ttm): | -2.33 |
| Div & Yield: | N/A (N/A) |
Quotes delayed, except where indicated otherwise. For consolidated real-time quotes (incl. pre/post market data), sign up for a free trial of Real-time Quotes.
Headlines
| Wed, Nov 25 | A Big Upgrade for Amylin Pharmaceuticalsat Motley Fool |
| Tue, Nov 24 | Cel-Sci's History of Disappearing Drugs: BioBuzzat TheStreet.com |
| Tue, Nov 24 | Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care ConferencePR Newswire |
| Tue, Nov 24 | BioCryst Bull Blames Conspiracy for Stock's Fall: BioBuzzat TheStreet.com |
| Mon, Nov 23 | The Side Effect of Developing Obesity Drugsat Motley Fool |
| Mon, Nov 23 | Poniard Finds Cash to Keep Lights On: BioBuzzat TheStreet.com |
| Mon, Nov 23 | Cel-Sci Chairman Sells Stock, Despite Sweetheart Loan Deal: BioBuzzat TheStreet.com |
| Mon, Nov 23 | FDA Issues New Obesity Drug Heart Warning: BioBuzzat TheStreet.com |
| Wed, Nov 18 | Obesity and ED: Two Big Markets, One Tiny Companyat Minyanville.com |
| Wed, Nov 18 | Vivus shares rise on positive avanafil study dataAP |
Quotes delayed, except where indicated otherwise.
Delay times are 15 mins for NASDAQ, NYSE and Amex.See also delay times for other exchanges.